Claritev Earnings Call Signals AI-Fueled Growth Path

Claritev Corporation ((CTEV)) has held its Q1 earnings call. Read on for the main highlights of the call.

Claritev Corporation’s latest earnings call painted a broadly upbeat picture, with management emphasizing better-than-expected revenue and EBITDA, robust sales momentum, and early payoffs from AI-driven efficiencies. Executives acknowledged some near-term pressure from cash consumption and lower-margin services, but framed these as deliberate investments designed to sustain growth and expand the company’s addressable market.

Revenue Growth and Solid Profitability

Claritev reported first-quarter revenue of $244.7 million, up 5.8% year over year, alongside adjusted EBITDA of $146.9 million, a 3.4% increase that translates to a hefty 60% margin. Management responded by nudging the low end of its full-year revenue outlook higher to a range of $985 million to $1.0 billion, while reaffirming its projection for adjusted EBITDA of $605 million to $615 million, implying margins of 61% to 62%.

ACV Bookings Surge and Sales Engine Accelerates

Annual contract value bookings hit $44.1 million in the quarter, a strong start toward Claritev’s $80 million to $100 million full-year target, which would represent 20% to 50% growth versus last year. The company highlighted a 70% year-over-year jump in pipeline, 19 deals above $100,000 in ACV, and nine seven-figure contracts, with average deal size more than doubling and nearly three-quarters of bookings coming from cross-sell and upsell activity.

Cash Flow Trajectory Shows Improvement

Claritev generated $36.8 million in unlevered free cash flow in the first quarter, up 181% from the prior year, underscoring improving underlying cash economics. Management reiterated its expectation of positive free cash flow for the full year and kept capital expenditure plans intact at $160 million to $170 million, signaling confidence in funding growth without sacrificing balance sheet discipline.

Core Products and Mix Tailwinds

The company’s flagship claims intelligence offering, Data iSight, grew 8.4% in the quarter and remained a key driver of overall performance, while network and payment integrity businesses delivered in line or slightly above internal expectations. Management acknowledged modest volume declines in PSAV claims but noted that pricing, mix, and higher-acuity claims more than offset the drop, sustaining revenue growth in that segment.

Strategic Wins Extend Market Reach

Claritev expanded its footprint with a notable agreement to build a custom network for the World Trade Center Health Program, marking a meaningful entry into the public sector through a partnership with GDIT. The company also landed a major contract with a top-five health system operating more than 700 facilities, a win management linked directly to its acquisition of OPCG and the ramp-up of its newly launched services business.

AI and Automation Lift Operational Efficiency

Management showcased tangible productivity gains from AI and automation, noting that AI-powered coding tools nearly doubled engineering output without additional headcount. Claritev also deployed a provider contact agent that more than halved process times and saved over 2,000 hours, while an automated invoice system now processes thousands of invoices daily with near-perfect accuracy, freeing staff and reducing costs.

Improving Revenue Visibility from ACV

Claritev expects newly signed contracts to convert into revenue within six to twelve months, giving management greater confidence in its growth trajectory and its ability to hit bookings targets. The company guided to roughly flat sequential revenue in the second quarter, followed by 3% to 5% growth in the back half of the year as ACV ramps, underpinning its commitment to the full-year outlook.

PSAV Volume Softness and Mix Dependence

While core products performed well, management noted modest declines in PSAV claim volumes during the quarter, though it did not quantify the drop. The company leaned on favorable rate and mix dynamics, plus higher-acuity claims, to keep savings per claim and revenue in that line growing despite the volume softness, suggesting some sensitivity to future volume trends.

Cash Consumption and Interest Burden Timing

The quarter was described as a cash-consumption period, with reported free cash flow use of $92.5 million largely tied to working capital needs and fully annualized cash interest following last year’s refinancing. Management cautioned that both the first and third quarters are likely to remain cash-consumption periods in the near term, even as underlying free cash flow improves on a normalized basis.

Services Investments Pressure Margins Near Term

Claritev is leaning into services offerings in provider and public sector markets, expecting these to represent about 20% of total ACV at the midpoint of guidance. However, services margins are roughly half those of the core business while ramping, and the company plans to invest an additional $20 million to $25 million to support this build-out, creating a temporary drag on blended margins until scale and cross-sell economics kick in.

One-Off Prior-Year Revenue Skews Comparisons

Management warned that one-time P&C revenue and other non-recurring items booked last year, including multi-million-dollar quarterly contributions, will distort year-over-year comparisons. These prior-year boosts will create a headwind for reported growth in some quarters, complicating headline metrics even as underlying operational momentum remains positive.

Profit Growth Trails Revenue on Investment Cycle

Adjusted EBITDA increased 3.4% year over year, trailing the 5.8% revenue growth rate and highlighting the impact of mix shifts and incremental spending on services and technology. Executives framed this as a conscious invest-to-grow phase, indicating that profitability expansion is expected to resume as newer contracts ramp, services scale, and AI-driven efficiencies further lower costs.

Managing Regulatory and Market Unknowns

The call also acknowledged regulatory and market uncertainties, including potential changes around Medicare Advantage concurrent review that could influence claim volumes and demand over time. Management downplayed any immediate impact but stressed that it is closely monitoring the landscape and believes Claritev’s diversified portfolio and growing pipeline provide resilience against sudden shifts.

Guidance Reinforces Confidence in Growth Path

Claritev raised the low end of its full-year revenue outlook to $985 million while keeping the top end at $1.0 billion and reaffirming adjusted EBITDA guidance of $605 million to $615 million, implying mid-single-digit EBITDA dollar growth on a like-for-like basis. The company backed this outlook with strong first-quarter metrics, a 70% larger pipeline, an $80 million to $100 million ACV target, increased services investment, and an expectation that cash conversion rates normalize toward pre-2025 levels by year-end.

Claritev’s earnings call underscored a company leaning into growth, using AI and targeted investments to expand into new markets while still delivering high margins and improved cash flow. Investors will need to weigh temporary margin pressure, cash-consumption seasonality, and regulatory risks against strengthening ACV bookings, rising revenue visibility, and management’s conviction that today’s investments will support durable growth over the next several years.